Actuate Therapeutics, Inc. (ACTU)
Last updated: 2026-10-28 19:18:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Actuate Therapeutics, Inc. (ACTU) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.37, with a market capitalization of $12.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.35 to $7.90. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$12.68M | |
$0.40 | |
$25.55 | |
$0.35 | |
$0.40 | |
261.17K | |
395.83K | |
-- | |
$7.90 | |
$0.35 | |
-- | |
-- |
Actuate Therapeutics, Inc. (ACTU) Stock Price Today
Actuate Therapeutics, Inc. (ACTU) is currently trading at $0.37 as of 2026-10-28 19:16:00, down 6.88% ($0.03) from the previous close of $0.40
During today's regular trading session, ACTU has traded between $0.35 and $25.55, with a trading volume of 261.17K shares. The current price is near the lower end of today's range.
Actuate Therapeutics, Inc. (ACTU) 7-Day Stock Price Change
Over the past seven days, Actuate Therapeutics, Inc. (ACTU) moved from $0.60 to $0.37, representing a decline of 37.90% ($0.23).
The stock traded between $0.35 and $0.71 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 593.36 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
ACTU 52-Week Price Position
Position in Range: 0.3%
ACTU is currently trading at $0.37, placing it 0.3% of the way from its 52-week low of $0.35 to its 52-week high of $7.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Actuate Therapeutics, Inc. (ACTU)?
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Actuate Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Actuate Therapeutics, Inc. (ACTU) Stock on MEXC
Eligible investors can buy real shares of Actuate Therapeutics, Inc. (ACTU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Actuate Therapeutics, Inc. (ACTU) stock price today?
2.Is ACTU stock going up or down today?
3.What is ACTU pre-market price?
4.What is ACTU after-hours price?
5.Is ACTU stock trading now?
6.Where does ACTU sit relative to its 52-week high and low?
7.What sector is Actuate Therapeutics, Inc. in?
8.What is Actuate Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is ACTU valued in terms of P/E ratio and EPS?
10.Does Actuate Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ACTU Stock Calculator
Estimate the value between ACTU shares and USD.
ACTU Shares to USD
1.00 ACTU shares = 0.372 USD
Calculations are estimates based on the latest available price and are for reference only.


